{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:14:51Z","timestamp":1783574091798,"version":"3.55.0"},"reference-count":111,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have historically hindered further research into this area. Nevertheless, concurrent with the rise in SUDs and other mental health conditions, researchers have again turned their attention to these compounds, searching for differing pharmacological targets as well as more holistic treatments that might increase patient adherence and efficacy. The aim of this review is to examine the emerging evidence-based data with regards to the therapeutic treatment of SUDs with the psychedelic compounds psilocybin, ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ayahuasca, ibogaine and peyote.<\/jats:p>","DOI":"10.3390\/ph17111484","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:30:53Z","timestamp":1730784653000},"page":"1484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders"],"prefix":"10.3390","volume":"17","author":[{"given":"Tamara","family":"Valdez","sequence":"first","affiliation":[{"name":"College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbhi","family":"Patel","sequence":"additional","affiliation":[{"name":"College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaphone","family":"Senesombath","sequence":"additional","affiliation":[{"name":"College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Hatahet-Donovan","sequence":"additional","affiliation":[{"name":"College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-7253","authenticated-orcid":false,"given":"Mary","family":"Hornick","sequence":"additional","affiliation":[{"name":"College of Science, Health and Pharmacy, Roosevelt University, Schaumburg, IL 60173, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"ref_1","unstructured":"American Psychiatric Association (2024, June 24). What Is a Substance Use Disorder?. Available online: https:\/\/www.psychiatry.org\/patients-families\/addiction-substance-use-disorders\/what-is-a-substance-use-disorder."},{"key":"ref_2","unstructured":"Substance Abuse and Mental Health Services Administration (2024). Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1080\/07853890.2022.2100926","article-title":"How the war on drugs impacts social determinants of health beyond the criminal legal system","volume":"54","author":"Cohen","year":"2022","journal-title":"Ann. Med."},{"key":"ref_4","unstructured":"(2024, April 26). Alcohol and Drug Abuse Statistics (Facts About Addiction). Available online: https:\/\/americanaddictioncenters.org\/addiction-statistics."},{"key":"ref_5","unstructured":"(2024). War on Drugs, Encyclopedia Britannica."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000468273","article-title":"A review of LSD treatment in alcoholism","volume":"6","author":"Abuzzahab","year":"1971","journal-title":"Int. Pharmacopsychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jad.2023.01.005","article-title":"Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial","volume":"325","author":"Ahmed","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am. J. Drug Alcohol. Abus."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2045125320986634","DOI":"10.1177\/2045125320986634","article-title":"Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine","volume":"11","author":"Berlowitz","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Su, H., Ye, T., Cao, S., and Hu, C. (2024). Understanding the shift to compulsion in addiction: Insights from personality traits, social factors, and neurobiology. Front. Psychol., 15.","DOI":"10.3389\/fpsyg.2024.1416222"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11042","DOI":"10.1073\/pnas.191352698","article-title":"DeltaFosB: A sustained molecular switch for addiction","volume":"98","author":"Nestler","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1523\/JNEUROSCI.2542-04.2004","article-title":"Induction of deltaFosB in reward-related brain structures after chronic stress","volume":"24","author":"Perrotti","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuroscience.2012.04.012","article-title":"Intermittent social defeat stress enhances mesocorticolimbic DeltaFosB\/BDNF co-expression and persistently activates corticotegmental neurons: Implication for vulnerability to psychostimulants","volume":"212","author":"Nikulina","year":"2012","journal-title":"Neuroscience"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.psyneuen.2018.05.013","article-title":"Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts","volume":"94","author":"Michels","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Myint, A.M., and Halaris, A. (2022). Imbalances in Kynurenines as Potential Biomarkers in the Diagnosis and Treatment of Psychiatric Disorders. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.913303"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Domanegg, K., Sommer, W.H., and Meinhardt, M.W. (2023). Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism. Cells, 12.","DOI":"10.3390\/cells12060963"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40292-020-00396-9","article-title":"Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice","volume":"27","author":"Giulietti","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/add.15647","article-title":"Clinical management of the alcohol withdrawal syndrome","volume":"117","author":"Day","year":"2022","journal-title":"Addiction"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction","volume":"154","author":"Christie","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1353-1131(03)00003-8","article-title":"The pathophysiology of cocaine abuse","volume":"10","author":"White","year":"2003","journal-title":"J. Clin. Forensic Med."},{"key":"ref_30","unstructured":"VanFrank, B., Malarcher, A., Cornelius, M.E., Schecter, A., Jamal, A., and Tynan, M. (2022). Adult Smoking Cessation\u2014United States, 2022. MMWR Morbidity and Mortality Weekly Report, Center for Disease Control and Prevention."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.04.003","article-title":"Predicting relapse after alcohol use disorder treatment in a high-risk cohort: The roles of anhedonia and smoking","volume":"126","author":"Nguyen","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Poireau, M., Milpied, T., Maillard, A., Delmaire, C., Volle, E., Bellivier, F., Icick, R., Azuar, J., Marie-Claire, C., and Bloch, V. (2022). Biomarkers of Relapse in Cocaine Use Disorder: A Narrative Review. Brain Sci., 12.","DOI":"10.3390\/brainsci12081013"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): A review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoact. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e230109","DOI":"10.1136\/bcr-2019-230109","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: Preliminary data on the first four participants","volume":"12","author":"Sessa","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol. Abus."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2016.39","article-title":"Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial","volume":"22","author":"Dakwar","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/02791072.2018.1447174","article-title":"Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence?","volume":"50","author":"Cruz","year":"2018","journal-title":"J. Psychoact. Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mash, D.C., Duque, L., Page, B., and Allen-Ferdinand, K. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00529"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02159243","article-title":"[Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0010-440X(70)90204-X","article-title":"Hallucinogenic drugs in the treatment of alcoholism: A two-year follow-up","volume":"11","author":"Faillace","year":"1970","journal-title":"Compr. Psychiatry"},{"key":"ref_46","first-page":"81","article-title":"Treatment of alcoholism with psychotomimetic drugs. A follow-up study","volume":"20","author":"Rydzynski","year":"1978","journal-title":"Act. Nerv. Super."},{"key":"ref_47","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Library of Medicine, and National Center for Biotechnology Information (2024, October 01). Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_48","first-page":"157","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Griffiths","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol. Abus."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jones, G., Lipson, J., and Nock, M.K. (2022). Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14809-3"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hornick, M.G., and Stefanski, A. (2023). Hallucinogenic potential: A review of psychoplastogens for the treatment of opioid use disorder. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1221719"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lee, Y.K., Gold, M.S., Blum, K., Thanos, P.K., Hanna, C., and Fuehrlein, B.S. (2023). Opioid use disorder: Current trends and potential treatments. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1274719"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/02791072.2023.2190319","article-title":"Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review","volume":"55","author":"Sharma","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Jones, G.M., and Nock, M.K. (2022). Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-06580-2"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/psymed.2023.0012","article-title":"Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings","volume":"1","author":"Nicholas","year":"2023","journal-title":"Psychedelic Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(70)91273-0","article-title":"Ketamine as an induction agent in anaesthetics","volume":"1","author":"Dundee","year":"1970","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"172547","DOI":"10.1016\/j.ejphar.2019.172547","article-title":"Ketamine applications beyond anesthesia\u2014A literature review","volume":"860","author":"Nowacka","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40268-015-0081-0","article-title":"Ketamine as a potential treatment for suicidal ideation: A systematic review of the literature","volume":"15","author":"Reinstatler","year":"2015","journal-title":"Drugs R. D"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","article-title":"The role of ketamine in treatment-resistant depression: A systematic review","volume":"12","author":"Serafini","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2018.01.022","article-title":"Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats","volume":"668","author":"Rezvani","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Goldfine, C.E., Tom, J.J., Im, D.D., Yudkoff, B., Anand, A., Taylor, J.J., Chai, P.R., and Suzuki, J. (2023). The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: A scoping review. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1141836"},{"key":"ref_65","first-page":"e38498","article-title":"Ketamine Treatment for Alcohol Use Disorder: A Systematic Review","volume":"15","author":"Kelson","year":"2023","journal-title":"Cureus"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/0269881120970879","article-title":"Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial","volume":"35","author":"Rothberg","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e29693","DOI":"10.1002\/pbc.29693","article-title":"Low-dose ketamine infusions reduce opioid use in pediatric and young adult oncology patients","volume":"69","author":"Anghelescu","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"103170","DOI":"10.1016\/j.ijoa.2021.103170","article-title":"Low-dose ketamine infusion for post-cesarean delivery analgesia in patients with opioid use disorder","volume":"47","author":"Cobb","year":"2021","journal-title":"Int. J. Obstet. Anesth."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/09540261.2023.2229430","article-title":"Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: A review of the human evidence","volume":"35","author":"Oliveira","year":"2023","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/ADM.0000000000000483","article-title":"Comparison of Perioperative Systemic Lidocaine or Systemic Ketamine in Acute Pain Management of Patients With Opioid Use Disorder After Orthopedic Surgery","volume":"13","author":"Sahmeddini","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J. Psychoact. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"key":"ref_76","unstructured":"Clark-Schoeb, E.B. (2024). Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD, Lykos Therapeutics."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Jones, J.L. (2023). Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1096298"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00213-015-4162-0","article-title":"Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities","volume":"233","author":"Soler","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Barbosa, P.C.R., Tofoli, L.F., Bogenschutz, M.P., Hoy, R., Berro, L.F., Marinho, E.A.V., Areco, K.N., and Winkelman, M.J. (2018). Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca. Front. Psychiatry, 9.","DOI":"10.3389\/fpsyt.2018.00136"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/15672050113109990001","article-title":"Ibogaine in the treatment of substance dependence","volume":"6","author":"Brown","year":"2013","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0099-9598(01)56018-6","article-title":"A contemporary history of ibogaine in the United States and Europe","volume":"56","author":"Alper","year":"2001","journal-title":"Alkaloids Chem. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1476-5381.1996.tb15253.x","article-title":"Neurochemical and behavioural interactions between ibogaine and nicotine in the rat","volume":"117","author":"Benwell","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1369-1600.2010.00251.x","article-title":"Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration","volume":"15","author":"Carnicella","year":"2010","journal-title":"Addict. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0269881115584461","article-title":"Noribogaine reduces nicotine self-administration in rats","volume":"29","author":"Chang","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/bs.pbr.2018.08.002","article-title":"A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder","volume":"242","author":"Barsuglia","year":"2018","journal-title":"Prog. Brain Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jflm.2013.06.032","article-title":"Ibogaine related sudden death: A case report","volume":"20","author":"Papadodima","year":"2013","journal-title":"J. Forensic Leg. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17425255.2021.1944099","article-title":"Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse","volume":"17","author":"Luz","year":"2021","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/02791072.2016.1180467","article-title":"Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report","volume":"48","author":"Wood","year":"2016","journal-title":"J. Psychoact. Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2018.1487607","article-title":"A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification","volume":"50","author":"Davis","year":"2018","journal-title":"J. Psychoact. Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"J. Psychoact. Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures","volume":"914","author":"Mash","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"109294","DOI":"10.1016\/j.neuropharm.2022.109294","article-title":"Mescaline: The forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"366","DOI":"10.15288\/jsad.2019.80.366","article-title":"Examination of Recreational and Spiritual Peyote Use Among American Indian Youth","volume":"80","author":"Prince","year":"2019","journal-title":"J. Stud. Alcohol. Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes","volume":"4","author":"Haas","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejn.14630","article-title":"Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants","volume":"53","author":"Duman","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jcpt.12497","article-title":"What is the mechanism of Ketamine\u2019s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities","volume":"42","author":"Strasburger","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness","volume":"17","author":"Hamill","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/02791072.2019.1598603","article-title":"Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder","volume":"51","author":"Brown","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1556\/2054.2021.00152","article-title":"A Narrative Review of the Pharmacological, Cultural and Psychological Literature on Ibogaine","volume":"5","author":"Underwood","year":"2021","journal-title":"J. Psychedelic Stud."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","article-title":"Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil","volume":"184","author":"Grob","year":"1996","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"Syed","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.3402\/ehtj.v4i0.7107","article-title":"The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use","volume":"4","author":"Kalsi","year":"2011","journal-title":"Emerg. Health Threat. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"109056","DOI":"10.1016\/j.drugalcdep.2021.109056","article-title":"Test-retest reliability and cross-cultural applicability of DSM-5 adopted diagnostic criteria for ketamine use disorders","volume":"228","author":"Fitzgerald","year":"2021","journal-title":"Drug Alcohol. Depend."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/acschemneuro.8b00155","article-title":"Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine","volume":"9","author":"Dunlap","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425255.2020.1749262","article-title":"MDMA interactions with pharmaceuticals and drugs of abuse","volume":"16","author":"Papaseit","year":"2020","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/ADM.0000000000001188","article-title":"Prevalence and Correlates of Past Year Ecstasy\/MDMA Use in the United States","volume":"17","author":"Yang","year":"2023","journal-title":"J. Addict. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:30Z","timestamp":1760113590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":111,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111484"],"URL":"https:\/\/doi.org\/10.3390\/ph17111484","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}